Personalized digital therapeutics
for the treatment of diseases
with high unmet medical need

OUR STORY

WELT was founded in 2016 as a spin-off of SAMSUNG to explore the intersection of healthcare and technology

 
메인2.jpg

MISSION

We create personalized digital therapeutics that combine our expertise in sensor and digital biomarker technologies with therapeutic contents for the treatment of diseases with high unmet medical need

 

DTx Leader in Korea

WELT served as an industry advisor for the Ministry of Food
and 
Drug Safety (KFDA) on digital therapeutics

 

 


 

WELT partnered with multiple government institutions
re: adoption and implementation of digital therapeutics in Korea

 

 


 

WELT co-chairs the DTA APAC Working Group to promote
the industry in the region

Group 189.png
Group 191.png
Group 190.png
Group 192.png
 

PRODUCT PIPELINE

 
AdobeStock_335731060 2.png

INVESTORS & PARTNERS

At WELT, we believe that an ideal digital therapeutics company should strategize like pharma, execute like tech company, and build a culture resembling that of gaming company. Our group of investors and partners reflects that belief.

INVESTORS

Group 189.png
한독3.png
포스코3.png

PARTNERS

Group 190.png